Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE4.1000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.0100/ 1
- Ask / Lots4.2500/ 2
- Open / Previous Close--- / 4.1000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 3159 | 4.01 |
| 09:36 ET | 5224 | 4.015 |
| 09:38 ET | 1833 | 4.02 |
| 09:41 ET | 2991 | 4.01 |
| 09:43 ET | 1561 | 4.03 |
| 09:45 ET | 770 | 4.02 |
| 09:48 ET | 600 | 4.05 |
| 09:50 ET | 2134 | 4.06 |
| 09:52 ET | 1989 | 4.07 |
| 09:54 ET | 5309 | 4.07 |
| 09:56 ET | 5001 | 4.065 |
| 09:57 ET | 200 | 4.06 |
| 09:59 ET | 6069 | 4.075 |
| 10:01 ET | 752 | 4.08 |
| 10:06 ET | 150 | 4.075 |
| 10:08 ET | 4892 | 4.065 |
| 10:10 ET | 400 | 4.055 |
| 10:12 ET | 600 | 4.0499 |
| 10:14 ET | 200 | 4.07 |
| 10:15 ET | 4566 | 4.08 |
| 10:17 ET | 300 | 4.075 |
| 10:19 ET | 8261 | 4.06 |
| 10:21 ET | 2400 | 4.07 |
| 10:26 ET | 6332 | 4.0783 |
| 10:28 ET | 900 | 4.07 |
| 10:30 ET | 1384 | 4.065 |
| 10:32 ET | 100 | 4.06 |
| 10:33 ET | 400 | 4.05 |
| 10:35 ET | 4288 | 4.055 |
| 10:37 ET | 7052 | 4.055 |
| 10:39 ET | 1100 | 4.075 |
| 10:42 ET | 1028 | 4.09 |
| 10:44 ET | 5725 | 4.08 |
| 10:46 ET | 412 | 4.08 |
| 10:48 ET | 13346 | 4.105 |
| 10:50 ET | 2488 | 4.08 |
| 10:51 ET | 730 | 4.09 |
| 10:53 ET | 4300 | 4.1 |
| 10:55 ET | 21729 | 4.125 |
| 10:57 ET | 21156 | 4.125 |
| 11:00 ET | 7699 | 4.145 |
| 11:02 ET | 9738 | 4.16 |
| 11:04 ET | 5126 | 4.16 |
| 11:06 ET | 4517 | 4.17 |
| 11:08 ET | 3904 | 4.165 |
| 11:09 ET | 7400 | 4.185 |
| 11:11 ET | 3050 | 4.185 |
| 11:13 ET | 600 | 4.185 |
| 11:15 ET | 5089 | 4.185 |
| 11:18 ET | 3360 | 4.185 |
| 11:20 ET | 2000 | 4.1801 |
| 11:22 ET | 8978 | 4.185 |
| 11:26 ET | 11306 | 4.2 |
| 11:27 ET | 1764 | 4.195 |
| 11:29 ET | 300 | 4.1999 |
| 11:33 ET | 1350 | 4.205 |
| 11:36 ET | 5029 | 4.2183 |
| 11:38 ET | 9734 | 4.2083 |
| 11:40 ET | 2625 | 4.205 |
| 11:42 ET | 13888 | 4.175 |
| 11:44 ET | 1870 | 4.1687 |
| 11:45 ET | 59613 | 4.145 |
| 11:47 ET | 600 | 4.145 |
| 11:49 ET | 14744 | 4.135 |
| 11:51 ET | 18420 | 4.13 |
| 11:54 ET | 3945 | 4.125 |
| 12:00 ET | 100 | 4.125 |
| 12:02 ET | 475 | 4.13 |
| 12:03 ET | 100 | 4.13 |
| 12:05 ET | 700 | 4.125 |
| 12:07 ET | 700 | 4.13 |
| 12:09 ET | 1516 | 4.135 |
| 12:12 ET | 1022 | 4.135 |
| 12:14 ET | 3153 | 4.125 |
| 12:18 ET | 1422 | 4.115 |
| 12:21 ET | 1000 | 4.1108 |
| 12:23 ET | 1153 | 4.1 |
| 12:25 ET | 200 | 4.1 |
| 12:27 ET | 132 | 4.1 |
| 12:32 ET | 300 | 4.105 |
| 12:34 ET | 100 | 4.11 |
| 12:36 ET | 100 | 4.105 |
| 12:38 ET | 100 | 4.105 |
| 12:39 ET | 418 | 4.105 |
| 12:41 ET | 785 | 4.09 |
| 12:43 ET | 350 | 4.095 |
| 12:45 ET | 300 | 4.095 |
| 12:50 ET | 400 | 4.105 |
| 12:52 ET | 418 | 4.11 |
| 12:54 ET | 3267 | 4.1 |
| 12:56 ET | 10825 | 4.095 |
| 12:57 ET | 15039 | 4.095 |
| 01:01 ET | 318 | 4.095 |
| 01:03 ET | 100 | 4.1 |
| 01:06 ET | 300 | 4.105 |
| 01:08 ET | 2939 | 4.095 |
| 01:12 ET | 1501 | 4.09 |
| 01:14 ET | 200 | 4.09 |
| 01:15 ET | 400 | 4.095 |
| 01:17 ET | 500 | 4.09 |
| 01:19 ET | 300 | 4.08 |
| 01:28 ET | 300 | 4.065 |
| 01:32 ET | 2412 | 4.08 |
| 01:33 ET | 300 | 4.06 |
| 01:39 ET | 100 | 4.065 |
| 01:42 ET | 130 | 4.065 |
| 01:44 ET | 617 | 4.055 |
| 01:48 ET | 2000 | 4.06 |
| 01:50 ET | 377 | 4.07 |
| 01:51 ET | 1100 | 4.08 |
| 01:53 ET | 3791 | 4.095 |
| 01:55 ET | 200 | 4.095 |
| 01:57 ET | 952 | 4.095 |
| 02:02 ET | 100 | 4.1 |
| 02:06 ET | 6577 | 4.09 |
| 02:08 ET | 300 | 4.09 |
| 02:09 ET | 1085 | 4.09 |
| 02:13 ET | 100 | 4.089 |
| 02:15 ET | 1923 | 4.095 |
| 02:18 ET | 305 | 4.09 |
| 02:20 ET | 500 | 4.1 |
| 02:24 ET | 1342 | 4.1 |
| 02:27 ET | 507 | 4.1 |
| 02:31 ET | 648 | 4.095 |
| 02:33 ET | 400 | 4.099 |
| 02:36 ET | 200 | 4.1 |
| 02:38 ET | 3027 | 4.1 |
| 02:42 ET | 1700 | 4.1 |
| 02:44 ET | 1300 | 4.11 |
| 02:45 ET | 9336 | 4.1 |
| 02:47 ET | 500 | 4.085 |
| 02:49 ET | 200 | 4.09 |
| 02:51 ET | 300 | 4.095 |
| 02:54 ET | 14503 | 4.11 |
| 02:56 ET | 500 | 4.11 |
| 02:58 ET | 200 | 4.12 |
| 03:00 ET | 200 | 4.125 |
| 03:02 ET | 1107 | 4.13 |
| 03:03 ET | 4104 | 4.115 |
| 03:05 ET | 200 | 4.12 |
| 03:07 ET | 400 | 4.12 |
| 03:09 ET | 920 | 4.115 |
| 03:12 ET | 200 | 4.115 |
| 03:14 ET | 1750 | 4.115 |
| 03:16 ET | 2310 | 4.11 |
| 03:20 ET | 4954 | 4.09 |
| 03:21 ET | 700 | 4.09 |
| 03:23 ET | 600 | 4.1 |
| 03:25 ET | 100 | 4.1 |
| 03:27 ET | 400 | 4.1 |
| 03:30 ET | 928 | 4.1 |
| 03:32 ET | 3069 | 4.09 |
| 03:34 ET | 949 | 4.085 |
| 03:36 ET | 3237 | 4.09 |
| 03:38 ET | 100 | 4.085 |
| 03:39 ET | 1390 | 4.1 |
| 03:41 ET | 4246 | 4.095 |
| 03:43 ET | 1200 | 4.0992 |
| 03:45 ET | 863 | 4.1 |
| 03:48 ET | 9174 | 4.1 |
| 03:50 ET | 1600 | 4.1 |
| 03:52 ET | 3688 | 4.09 |
| 03:54 ET | 3824 | 4.1 |
| 03:56 ET | 15406 | 4.1 |
| 03:57 ET | 1522 | 4.095 |
| 03:59 ET | 22408 | 4.1 |
Sep 17, 2024
DJ Mereo BioPharma Group Down Over 9%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk, from 1:42PM ET on Tuesday Sep 17, 2024 by Dow Jones
1:42PM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 16, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 12:21PM ET on Monday Sep 16, 2024 by Dow Jones
12:21PM ET on Monday Sep 16, 2024 by Dow Jones
Sep 12, 2024
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference, from 5:35PM ET on Thursday Sep 12, 2024 by Dow Jones
5:35PM ET on Thursday Sep 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 635.2M | -12.4x | --- |
Immunome Inc | 861.2M | -2.5x | --- |
Mesoblast Ltd | 849.0M | -8.5x | --- |
CARGO Therapeutics Inc | 848.8M | -5.3x | --- |
Perspective Therapeutics Inc | 826.7M | -8.8x | --- |
Oruka Therapeutics Inc | 835.4M | -4.0x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $635.2M |
|---|---|
Revenue (TTM) | $10.6M |
Shares Outstanding | 153.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.97 |
EPS | $-0.33 |
Book Value | $0.47 |
P/E Ratio | -12.4x |
Price/Sales (TTM) | 59.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
